Dualys Bio

Website
AI,BioTech,DeepTech

Company Bio

Founders

LvlUp insightsGenerated from LvlUp’s portfolio data and the company’s own updates
Similar companies

More in the LvlUp portfolio

See all →

Building something ambitious?

LvlUp Ventures backs founders from first check to late stage.

Apply for funding
Andrew Zorn, Scott McMenemy
Pre-Seed
United States
AI, BioTech, DeepTech
2026
1) enzyme variants sold as programmable research reagents to labs and biologics manufacturers (direct sales, no clinical development required); 2) disease programs (oncology first, then other disease areas) out-licensed to pharma partners on upfront and milestone terms; 3) long-term therapeutic co-development.

Building the first programmable protein editor: an enzyme that reads any protein sequence and cuts or joins it directly, the way CRISPR made DNA editing programmable. No binding pocket required. A new modality, not a better drug.